Cargando…

Antibody Peptide Based Antifungal Immunotherapy

Fungal infections still represent relevant human illnesses worldwide and some are accompanied by unacceptably high mortality rates. The limited current availability of effective and safe antifungal agents makes the development of new drugs and approaches of antifungal vaccination/immunotherapy every...

Descripción completa

Detalles Bibliográficos
Autores principales: Magliani, Walter, Conti, Stefania, Giovati, Laura, Zanello, Pier Paolo, Sperindè, Martina, Ciociola, Tecla, Polonelli, Luciano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Research Foundation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365853/
https://www.ncbi.nlm.nih.gov/pubmed/22675322
http://dx.doi.org/10.3389/fmicb.2012.00190
_version_ 1782234694499172352
author Magliani, Walter
Conti, Stefania
Giovati, Laura
Zanello, Pier Paolo
Sperindè, Martina
Ciociola, Tecla
Polonelli, Luciano
author_facet Magliani, Walter
Conti, Stefania
Giovati, Laura
Zanello, Pier Paolo
Sperindè, Martina
Ciociola, Tecla
Polonelli, Luciano
author_sort Magliani, Walter
collection PubMed
description Fungal infections still represent relevant human illnesses worldwide and some are accompanied by unacceptably high mortality rates. The limited current availability of effective and safe antifungal agents makes the development of new drugs and approaches of antifungal vaccination/immunotherapy every day more needed. Among them, small antibody(Ab)-derived peptides are arousing great expectations as new potential antifungal agents. In this topic, the search path from the study of the yeast killer phenomenon to the production of Ab-derived peptides characterized by in vitro and in vivo fungicidal activity will be focused. In particular, Abs that mimic the antimicrobial activity of a killer toxin (“antibiobodies”) and antifungal peptides derived from antibiobodies (killer peptide) and other unrelated Abs [complementarity determining regions (CDR)-based and constant region (Fc)-based synthetic peptides] are described. Mycological implications in terms of reevaluation of the yeast killer phenomenon, roles of antibiobodies in antifungal immunity, of β-glucans as antifungal targets and vaccines, and of Abs as sources of an unlimited number of sequences potentially active as new immunotherapeutic tools against fungal agents and related mycoses, are discussed.
format Online
Article
Text
id pubmed-3365853
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Frontiers Research Foundation
record_format MEDLINE/PubMed
spelling pubmed-33658532012-06-06 Antibody Peptide Based Antifungal Immunotherapy Magliani, Walter Conti, Stefania Giovati, Laura Zanello, Pier Paolo Sperindè, Martina Ciociola, Tecla Polonelli, Luciano Front Microbiol Microbiology Fungal infections still represent relevant human illnesses worldwide and some are accompanied by unacceptably high mortality rates. The limited current availability of effective and safe antifungal agents makes the development of new drugs and approaches of antifungal vaccination/immunotherapy every day more needed. Among them, small antibody(Ab)-derived peptides are arousing great expectations as new potential antifungal agents. In this topic, the search path from the study of the yeast killer phenomenon to the production of Ab-derived peptides characterized by in vitro and in vivo fungicidal activity will be focused. In particular, Abs that mimic the antimicrobial activity of a killer toxin (“antibiobodies”) and antifungal peptides derived from antibiobodies (killer peptide) and other unrelated Abs [complementarity determining regions (CDR)-based and constant region (Fc)-based synthetic peptides] are described. Mycological implications in terms of reevaluation of the yeast killer phenomenon, roles of antibiobodies in antifungal immunity, of β-glucans as antifungal targets and vaccines, and of Abs as sources of an unlimited number of sequences potentially active as new immunotherapeutic tools against fungal agents and related mycoses, are discussed. Frontiers Research Foundation 2012-06-01 /pmc/articles/PMC3365853/ /pubmed/22675322 http://dx.doi.org/10.3389/fmicb.2012.00190 Text en Copyright © 2012 Magliani, Conti, Giovati, Zanello, Sperindè, Ciociola and Polonelli. http://www.frontiersin.org/licenseagreement This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.
spellingShingle Microbiology
Magliani, Walter
Conti, Stefania
Giovati, Laura
Zanello, Pier Paolo
Sperindè, Martina
Ciociola, Tecla
Polonelli, Luciano
Antibody Peptide Based Antifungal Immunotherapy
title Antibody Peptide Based Antifungal Immunotherapy
title_full Antibody Peptide Based Antifungal Immunotherapy
title_fullStr Antibody Peptide Based Antifungal Immunotherapy
title_full_unstemmed Antibody Peptide Based Antifungal Immunotherapy
title_short Antibody Peptide Based Antifungal Immunotherapy
title_sort antibody peptide based antifungal immunotherapy
topic Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365853/
https://www.ncbi.nlm.nih.gov/pubmed/22675322
http://dx.doi.org/10.3389/fmicb.2012.00190
work_keys_str_mv AT maglianiwalter antibodypeptidebasedantifungalimmunotherapy
AT contistefania antibodypeptidebasedantifungalimmunotherapy
AT giovatilaura antibodypeptidebasedantifungalimmunotherapy
AT zanellopierpaolo antibodypeptidebasedantifungalimmunotherapy
AT sperindemartina antibodypeptidebasedantifungalimmunotherapy
AT ciociolatecla antibodypeptidebasedantifungalimmunotherapy
AT polonelliluciano antibodypeptidebasedantifungalimmunotherapy